Supernus Pharm (NASDAQ: SUPN) reported Q1 EPS of ($0.38), $0.03 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $9 million versus the consensus estimate of $9.94 million.

For earnings history and earnings-related data on Supernus Pharm (SUPN) click here.